Close Menu

Myriad

Under an agreement, Angsana's network of physicians in Hong Kong will be able to order Counsyl's expanded carrier screening test. 

Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.

The long-term pricing contract covers hereditary cancer testing, GeneSight, and a number of other diagnostics, but doesn't extend to coverage. 

The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.

The company said the number of lives now covered for EndoPredict has gone up to 109 million.

The molecular testing firm estimated that more than 70 percent of Medicare patients with prostate cancer will now have coverage for Prolaris.

A study conducted by Myriad Genetics and Ochsner Clinic showed that Prolaris scores were similar among African-American and non-African-American men. 

The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.

The firm reported total revenues of $196.9 million, compared to $190.5 million in Q3 2016, and beat the consensus Wall Street estimate of $189.1 million.

Myriad said it will submit a supplementary premarket approval application for its BRACAnalysis CDx, which the FDA originally approved in 2014.

Pages

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

In Science this week: three studies from the Ruminant Genome Project, and more.